press center press release

VBI Vaccines Inc. (Nasdaq: VBIV) to Ring The Nasdaq Stock Market Opening Bell

Published

ADVISORY, July 19, 2016 (GLOBE NEWSWIRE) --

What: 

VBI Vaccines Inc. (“VBI”) (Nasdaq:VBIV), a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Jeff Baxter, President and Chief Executive Officer, will ring the Opening Bell. 

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Wednesday, July 20, 2016 – 9:15 a.m. to 9:30 a.m. ET

VBI Media Contact:

Perri Maduri

617-830-3031 x124

pmaduri@vbivaccines.com

Nasdaq MarketSite:

Emily Pan

(646) 441-5120

emily.pan@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:

http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:

http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:

http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:

http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:

http://nasdaq.tumblr.com/

Webcast:

A live stream of the Nasdaq Opening Bell will be available at:

https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About VBI

VBI Vaccines Inc. (Nasdaq:VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vacis approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and nearly 17,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-

In This Story

NDAQ

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more